Clinical Trial Update: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy [Phase 4]

View source ↗

Summary

Phase 4 trial update on rifaximin in subjects with severe hepatic impairment and hepatic encephalopathy; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatic Encephalopathy | Phase 4 | Status: TERMINATED | Results posted: 2024-01-09